Source study found

Story checked

Blood cancer study links blood formation and bone health (opens in a new tab)

medicalxpress.com · 2026-10-09

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Blood cancer study links blood formation and bone health

medicalxpress.com · 2026-10-09

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

3 supported
1 not covered

Open claim evidence

The source study

Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study

Leukemia · 2026

Open source record

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredA specific DNMT3A mutation in blood-forming cells was associated with lower bone density, and people with low bone density or osteoporosis were more often found to have low calcium levels.View evidenceHide evidence

Why this verdict

The DNMT3A portion is supported: the abstract reports that DNMT3A mutation in the MDS cohort was associated with lower T-score. The calcium portion is not fully verifiable from the abstract-level profile as stated: the paper profile reports correlations between albumin-adjusted calcium/phosphate and T-scores, but the abstract does not provide direction, magnitude, or categorical evidence that people with low bone density or osteoporosis were more often found to have low calcium levels.

Study evidence

DNMT3A mutation was associated with lower T-score within the MDS cohort; the mutation occurrence in controls had no effect.-0.7

“Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect.”

Study evidence

Albumin-adjusted calcium levels were significantly correlated with T-scores within the MDS cohort after adjustment for age, sex, MDS duration, IPSS-M, and transfusion dependence.p < 0.0001

“Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence.”

Claim 2 of 4SupportedThe prospective BoHemE study shows that people with myelodysplastic syndromes already had lower bone density than age-matched controls at the start of the study and continued to lose bone density over three years.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the core claim: BoHemE prospectively assessed MDS patients and age-matched controls at baseline and 3 years; MDS patients had lower baseline T-scores than controls, and T-scores declined over 3 years. The claim is framed as an observed study finding rather than a causal claim, which matches the observational design.

Study evidence

At baseline, patients with MDS had lower bone mineral density (T-score) compared with age-matched controls.−0.2 (T-score); p < 0.05

“Within the Bone and Hematology in Elderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS (n = 111; 36% female) and age-matched controls (n = 84; 55% female) at baseline and after 3 years.”

Claim 3 of 4SupportedIf osteoporosis was present at the start of the study, it was associated with poorer overall survival.View evidenceHide evidence

Why this verdict

The profile states that baseline osteoporosis in MDS was associated with poorer overall survival, with p < 0.01. The story keeps the wording associational. However, the abstract does not provide hazard ratios, event counts, censoring details, or adjustment covariates.

Study evidence

Presence of osteoporosis at baseline was associated with poorer overall survival in patients with MDS.p < 0.01

“The presence of osteoporosis was associated with poor overall survival in MDS [p < 0.01].”

Claim 4 of 4SupportedThe study is presented as supporting the message that bone health should be monitored as part of comprehensive care for MDS and as opening new avenues for research into links between hematopoiesis, aging, and bone metabolism.View evidenceHide evidence

Why this verdict

The paper abstract explicitly concludes that bone health should be evaluated as part of MDS diagnostic work-up and clinical management, supporting the story’s quoted message about monitoring bone health. The 'opening new avenues' language is a speculative interpretive framing rather than a tested result, but it does not contradict the profile and is hedged as future research.

Study evidence

Authors conclude bone health evaluation should be included in MDS diagnostic work-up and clinical management, citing observed lower baseline T-scores in MDS (overall and especially in women), a DNMT3A-associated lower T-score within MDS, correlations of albumin-adjusted calcium and phosphate with T-scores, a decline in T-scores over 3 years, and an association of osteoporosis with poorer overall survival.Baseline T-score difference ≈ -0.2 (MDS vs controls); women with MDS ≈ -0.3; DNMT3A-associated difference ≈ -0.7; 3-year T-score decline ≈ -0.3

“In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Albumin-adjusted calcium and phosphate correlated with T-scores in MDS after adjustment for age, sex, MDS duration, IPSS-M score, and transfusion dependence.
The story reflects calcium only loosely as 'low calcium levels' accompanying low bone density/osteoporosis. It omits phosphate and the abstract’s adjusted-correlation framing, and the abstract profile does not verify the story’s categorical/directional calcium statement.
From prospective longitudinal observational cohort
Quality of life was lower in MDS patients than controls and remained stable over 3 years.
This supporting paper finding is not mentioned in the presented story claims or caveats.
From Prospective longitudinal cohort (BoHemE study)
Sex distribution differed between MDS patients and controls, which may affect between-group bone-density comparisons.
The paper profile flags the imbalance in sex distribution, but the story caveats do not mention it.
From Prospective longitudinal cohort

6 things the story did carry across

Prospective BoHemE cohort design: MDS patients were compared with age-matched controls at baseline and after 3 years using T-scores/bone health assessments.
Main bone-density finding: MDS patients had lower baseline T-scores than controls and showed T-score decline over follow-up.
Baseline osteoporosis was associated with poorer overall survival in MDS.
DNMT3A mutation in the MDS cohort was associated with lower T-score; no effect was reported in controls.
Authors’ clinical implication: bone health should be evaluated as part of MDS diagnostic work-up and clinical management.
Observational cohort design limits causal inference.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoProspectively compare bone health (BMD/T-scores and bone-specific serum markers) between patients with myelodysplastic neoplasms (MDS) and age-matched controls at baseline and over 3 years, and characterize longitudinal change.Prospective longitudinal cohortExpand

In plain English

Prospective longitudinal cohort (BoHemE) comparing bone health in patients with myelodysplastic neoplasms (MDS; n=111, 36% female) versus age-matched controls (n=84, 55% female) at baseline and after 3 years. Primary bone outcome was bone mineral density reported as T-score; bone-specific serum markers were also measured. At baseline MDS patients had lower T-scores than controls; T-scores declined over 3 years in MDS. Associations reported include lower T-scores in women with MDS and in MDS patients with DNMT3A mutation, correlations of albumin-adjusted calcium and phosphate with T-scores (independent of several covariates), worse quality of life in MDS, and an association between osteoporosis and poorer overall survival.

Key findings

At baseline, patients with MDS had lower bone mineral density (T-score) compared with age-matched controls.−0.2 (T-score); p < 0.05
Lower baseline T-score was primarily attributable to women with MDS.−0.3 (T-score in women with MDS vs controls); p < 0.05

“Within the Bone and Hematology in Elderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS (n = 111; 36% female) and age-matched controls (n = 84; 55% female) at baseline and after 3 years.”

What this piece can’t prove

Sex distribution differed between cohorts (MDS 36% female vs controls 55% female), which may influence between-group comparisons; abstract does not report sex-adjusted baseline comparisons beyond subgroup statements.
Abstract does not report attrition or missing data over 3 years, nor the number of participants contributing to longitudinal analyses.
Observational cohort design limits causal inference between MDS, mutations, serum markers, and bone outcomes; the abstract reports associations.

2 further details could not be confirmed from the summary.

2human in vivoTest associations between genetic alterations (e.g., DNMT3A mutation) and bone mineral density (T-score) within MDS (and assess whether similar patterns occur in controls).observational association analysis (genotype–phenotype)Expand

In plain English

Within the BoHemE cohort, presence of a DNMT3A mutation in patients with myelodysplastic neoplasms (MDS) was associated with a lower bone mineral density (T-score) compared to MDS patients without the mutation (reported effect −0.7; p < 0.05). The same mutation occurrence in the control group had no effect on T-score.

Key findings

DNMT3A mutation was associated with lower T-score within the MDS cohort; the mutation occurrence in controls had no effect.-0.7

“Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect.”

What this piece can’t prove

2 further details could not be confirmed from the summary.

3human in vivoAssess relationships between biochemical markers (albumin-adjusted calcium, phosphate) and T-scores in MDS, including adjusted analyses for clinical covariates.prospective longitudinal observational cohortExpand

In plain English

Within the prospective BoHemE cohort (MDS n=111), serum albumin-adjusted calcium and phosphate levels were measured and tested for association with bone mineral density (T-score). In the MDS cohort both markers showed statistically significant correlations with T-scores after multivariable adjustment for age, sex, MDS duration, IPSS-M score, and transfusion dependence (reported p-values: calcium p < 0.0001; phosphate p < 0.01).

Key findings

Albumin-adjusted calcium levels were significantly correlated with T-scores within the MDS cohort after adjustment for age, sex, MDS duration, IPSS-M, and transfusion dependence.p < 0.0001
Phosphate levels were significantly correlated with T-scores within the MDS cohort after the same multivariable adjustments.p < 0.01

“Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence.”

What this piece can’t prove

4 further details could not be confirmed from the summary.

4human in vivoEvaluate patient-reported quality of life (QoL) in MDS vs controls and its trajectory over 3 years.Prospective longitudinal cohort (BoHemE study)Expand

In plain English

In the prospective BoHemE cohort, patient-reported quality of life (QoL) was lower in patients with myelodysplastic neoplasms (MDS) than in age-matched controls (p < 0.01). The abstract states QoL remained stable over a 3-year follow-up. The QoL measurement instrument, numerical scores, and effect sizes are not reported in the abstract. Sample sizes reported: MDS n=111 (36% female), controls n=84 (55% female).

Key findings

Quality of life was lower in patients with MDS compared to age-matched controls (p < 0.01), and QoL remained stable over 3 years.

“Quality of life was lower in patients with MDS [p < 0.01], and remained stable over 3 years”

What this piece can’t prove

4 further details could not be confirmed from the summary.

5human in vivoAssess prognostic association of osteoporosis with overall survival in MDS.prospective longitudinal observational prognostic analysisExpand

In plain English

In the prospective longitudinal BoHemE study of patients with myelodysplastic neoplasms (MDS, n=111), the presence of osteoporosis at baseline was reported to be associated with poorer overall survival (p < 0.01). The abstract does not report effect size estimates (e.g., hazard ratio), number of events, or model covariates used in the survival analysis.

Key findings

Presence of osteoporosis at baseline was associated with poorer overall survival in patients with MDS.p < 0.01

“The presence of osteoporosis was associated with poor overall survival in MDS [p < 0.01].”

What this piece can’t prove

Unclear whether the association was adjusted for key prognostic factors (age, disease severity/IPSS-M, transfusion dependence, comorbidities).
The abstract provides a 3-year follow-up for BMD change but does not clarify duration of follow-up used for the survival analysis.

2 further details could not be confirmed from the summary.

6otherClinical implication/recommendation that bone health should be evaluated as part of MDS diagnostic work-up and management.interpretive recommendationExpand

In plain English

Authors recommend that bone health be evaluated as part of the diagnostic work-up and clinical management of patients with myelodysplastic neoplasms (MDS). This recommendation is stated in the abstract conclusion and is presented as an interpretive clinical implication derived from the BoHemE prospective longitudinal cohort data showing lower baseline bone mineral density (T-score) in MDS versus age-matched controls, sex-specific differences (lower T-score in women with MDS), an association of DNMT3A mutation with lower T-score, correlations between albumin-adjusted calcium/phosphate and T-scores in the MDS cohort, a decline in T-scores over 3 years, and an association between presence of osteoporosis and poorer overall survival.

Key findings

Authors conclude bone health evaluation should be included in MDS diagnostic work-up and clinical management, citing observed lower baseline T-scores in MDS (overall and especially in women), a DNMT3A-associated lower T-score within MDS, correlations of albumin-adjusted calcium and phosphate with T-scores, a decline in T-scores over 3 years, and an association of osteoporosis with poorer overall survival.Baseline T-score difference ≈ -0.2 (MDS vs controls); women with MDS ≈ -0.3; DNMT3A-associated difference ≈ -0.7; 3-year T-score decline ≈ -0.3

“In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.”

What this piece can’t prove

Recommendation is based on observational cohort data and author inference rather than a randomized or interventional study testing the recommendation.
Sample sizes: MDS n=111, controls n=84; subgroup analyses (e.g., by sex or mutation status) may have limited power.
Follow-up duration reported for bone density change was 3 years; longer-term outcomes and effects of interventions were not assessed.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer